Study Design
SOLID TUMORS
This was a phase I, open-label, ascending dose study in patients with advanced solid tumors (Trial registration ID: NCT02187848). The adaptive Bayesian study design, patient selection criteria, and results of the main dose-escalation cohort are published elsewhere (